Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Ibrutinib-related Atrial Fibrillation Dose Dependent: Insights From the WHO Pharmacovigilance Database

NCT06224452 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT06224452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Ibrutinib-related Atrial Fibrillation Dose Dependent: Insights From the WHO Pharmacovigilance Database
Lead sponsor
University Hospital, Caen
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2024
Completion date
July 1, 2024
Enrollment
18,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, hematological malignancy